Skip to content

OCRA Team

Meet Our Team

OCRA is fortunate to have a Board composed of distinguished leaders, a team of talented, caring Staff members, and a renowned Scientific Advisory Committee, who between them have decades of experience fighting ovarian and related gynecologic cancers. Passionate, knowledgeable, and innovative, they are dedicated to improving the lives of those touched by the disease through advancing research, creating imaginative, empathic support programs, encouraging industry collaboration, and fighting legislative battles on Capitol Hill.

Learn About Our Team Members

Never doubt that a small group of thoughtful committed citizens can change the world: indeed, it’s the only thing that ever has.
– Margaret Mead

Related Topics

Mission & Impact

Mission & Impact

OCRA is dedicated to improving treatments by advancing innovative research, supporting with expertise and empathy those affected by gynecologic cancers to ensure the best possible care and outcomes, raising awareness, and advocating for legislation that tangibly improves patients’ lives.

Learn more about our mission & impact

The Overview: July 2026

The Overview: July 2026

SummeRun Raises $260,000+ for Research, Hope and Progress Nearly one thousand runners, walkers, survivors, families, friends, and supporters showed up at Seattle’s Seward Park on Sunday, July 12th, for the 33rd annual Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, raising more than $260,000 for research and programs that support the gynecologic cancer community. The … Continued

Read more

Navigating Platinum-Resistant Ovarian Cancer: Everyday Health Shares Coping Strategies and OCRA Resources

Navigating Platinum-Resistant Ovarian Cancer: Everyday Health Shares Coping Strategies and OCRA Resources

In an article published by Everyday Health, “Coping With the Emotional Challenges of Platinum-Resistant Ovarian Cancer” (June 10, 2026), Ovarian Cancer Research Alliance (OCRA) community member Amanda Widro shares her experience navigating a platinum-resistant ovarian cancer diagnosis. Ovarian cancer is considered platinum-resistant when it recurs within six months of finishing platinum-based chemotherapy. Widro, who was … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.